Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer

Open-labeled, Randomized, Multicenter Phase III Study of Adjuvant Chemotherapy Comparing Bevacizumab Plus Cisplatin With Cisplatin Regimen in Malignant Pleural Effusion of Advanced Stage Non-Small-Cell Lung Cancer Patients

To determine the efficacy and Safety of intrapleural Bevacizumab and cisplatin as a treatment for malignant pleural effusions (MPE) in patients with non-small cell lung cancer (NSCLC).

Inclusion Criteria:

• Patients with advanced recurrent or progressive NSCLC proven cytohistologically
• Karnofsky performance status (KPS) ≥60
• Life expectancy ≥ 2 months
• No history of severe diseases of major organs including liver, heart, and kidney
• No previous intrapleural therapy
• Written informed consent

Exclusion Criteria:

• Active thoracic cavity or systemic bleeding
• Active pleural or systemic infection.
• Known sensitivity to Bevacizumab or Cisplatin
• Refusal to participate in the study.